Oppenheimer Comments on ACC Meeting

In a research report published earlier today, Oppenheimer commented on the American College of Cardiology's meeting, which provided data points for Medtronic MDT. According to Oppenheimer, “With the Resolute drug-eluting stent (DES) launch off to a strong start, MDT is targeting a doubling of its US DES share over the next 9-12 months, providing potential upside to our estimates. In renal denervation for hypertension, Simplicity data continue to look solid. MDT is focusing its R&D initiatives on iterating the device and pursuing new indications. Overall, within cardiovascular, we see MDT adjusting to today's market realities both by changing its interactions with customers (cross-selling across its multiple segments) and pursuing new markets (transcatheter heart valves, renal denervation, etc.).” Oppeneheimer maintains its Outperform rating and $45 PT on Medtronic, which closed yesterday at $40.00.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorReiterationAnalyst RatingsOppenheimer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!